Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Blood Cancer J. 2022 Jan 31;12(1):23. doi: 10.1038/s41408-022-00618-4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cell Line, Tumor
  • Cyclin-Dependent Kinase 9 / antagonists & inhibitors*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Mice
  • Myeloproliferative Disorders / drug therapy*
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • CDK9 protein, human
  • Cyclin-Dependent Kinase 9